Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reytense-P
- Development stage
- Unknown
- Lead developer
- Sanrey Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Reytense-P is a fixed-dose combination analgesic developed by Sanrey Therapeutics, containing flupirtine (100 mg) and paracetamol (325 mg). Flupirtine is a selective neuronal potassium channel opener (SNEPCO) that acts as a non-opioid, non-NSAID analgesic with muscle-relaxant properties by opening Kv7 (KCNQ) channels and indirectly antagonizing NMDA receptors. Paracetamol (acetaminophen) provides complementary analgesic and antipyretic effects, likely through the inhibition of cyclooxygenase enzymes in the central nervous system. This combination is utilized for the management of moderate to severe acute and chronic pain, including musculoskeletal conditions such as rheumatoid arthritis and osteoarthritis, as well as post-surgical pain, cancer-related pain, and tension headaches.
- Brand names
- Reytense-P
- Other names
- Flupirtine + ParacetamolFlupirtine maleate + Acetaminophen
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Reytense-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reytense-P.